Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that data showing new personalised therapeutic approaches for people with skin and lung cancer, plus new data with Avastin (bevacizumab) in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc.
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire Advanced BioHealing, Inc.
Pfizer To Present New Research From Fifteen Compounds
- Details
- Category: Pfizer
Pfizer Inc. will present more than 30 abstracts, including data from investigational compounds, axitinib,(1) crizotinib,(2) and bosutinib,(3) as well as data evaluating Sutent® (sunitinib malate), across multiple tumor types,(4,5) at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7.
Patrick Dempsey Teams up With Breakaway from Cancer(R)
- Details
- Category: Amgen
Patrick Dempsey is speaking out to help connect cancer patients to the free resources available to them via Amgen's Breakaway from Cancer(R) initiative.
New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application to the European Medicines Agency (EMA) for approval for people with BRAF V600 mutation-positive metastatic melanoma.
Pharmaceutical industry and university create Manchester Collaborative Centre for Inflammation Research
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK), The University of Manchester, and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research (MCCIR), a unique collaboration to establish a world-leading translational centre for inflammatory diseases.
Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
- Details
- Category: Abbott
Abbott's (NYSE: ABT) HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis.
More Pharma News ...
- Health economics substudy of PLATO shows BRILIQUE to be a cost effective treatment versus generic Clopidogrel
- Sanofi-aventis and Medicines for Malaria Venture Join Forces to Develop Innovative Malaria Drugs
- Novartis gains FDA approval for Afinitor®
- FDA approves linagliptin tablets for the treatment of type 2 diabetes
- Pfizer Reports First-Quarter 2011 Results
- Bayer off to a successful start to 2011
- Pfizer Announces Top-Line Results of Final Two Pivotal Phase 3 Trials of Tofacitinib (CP-690,550)